Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Background for new Investors / Traders
View:
Post by SundayMovies on Dec 17, 2022 11:51am

Background for new Investors / Traders

This baby is going to the moon and not coming back!

Of course, do your own due diligence but here is a starter:

Summary:
https://usanewsgroup.com/2022/11/27/market-uncertainty-is-creating-opportunities-that-have-somehow-been-overlooked/

Matt last interview:
https://www.youtube.com/watch?v=V8xlhTTJznU&t=350s
Comment by canadafan on Dec 17, 2022 12:39pm
I like your positive feedback & links to wide range of data. Your price predictions imho are quite conservative. talking in usd ( Nasdaq), the long term T.A. Shows $3++ as the next resistance. Granted needs to be above $2 first. Should see that Monday. once we enter the " grey zone" of trading. That being between Christmas & newyears. A few extra closed trading days, few are ...more  
Comment by TMAZZ21 on Dec 18, 2022 6:20pm
What happened to the European interest? Has that evalorated? What's the status? Any updates?
Comment by canadafan on Dec 18, 2022 7:17pm
There is a strong Europe interst in oncolitics biotech. Most signugicant being the Goblet trial with Roche. and The ongoing trials Aware-1, ( Solti, Spain & Portugal) and Bracelet ( Pfizer). visit the company web site,under investor presentation. All of your questions will be answered. Few are aware, let alone appreciate the global involvement Onc has. Canada, USA, Greater China region, & ...more  
Comment by Buckhenry on Dec 18, 2022 7:42pm
This post has been removed in accordance with Community Policy
Comment by canadafan on Dec 18, 2022 8:30pm
Actually, everything I post is substantiated by the company "investor presentation" please don't take my word, check it out. there are those who post under multiple names, personally attacking those who happen to take the time to read what is going on. a quick read, confirms  recent fast track designation for the Roche/ Onc pancreatic drug combination. recent update from China ...more  
Comment by Buckhenry on Dec 18, 2022 8:40pm
figures don't like... but liars figure. lets see. you said a few weeks ago you had some insider information but was not going to divulge... who is in kindergarten dufus
Comment by Buckhenry on Dec 18, 2022 8:49pm
this stock may very well do something at some point and these dufuses that continually post BS will take credit like they had a hand in the process. I do my own research and don't need their twist and BS comments. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities